1dxw: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='1dxw' size='340' side='right'caption='[[1dxw]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | <StructureSection load='1dxw' size='340' side='right'caption='[[1dxw]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[1dxw]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1DXW OCA]. For a <b>guided tour on the structure components</b> use [ | <table><tr><td colspan='2'>[[1dxw]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/9hepc 9hepc]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1DXW OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1DXW FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2ZF:N-(TERT-BUTOXYCARBONYL)-L-ALPHA-GLUTAMYL-N-[(1R)-1-(CARBOXYCARBONYL)-3,3-DIFLUOROPROPYL]-L-LEUCINAMIDE'>2ZF</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2ZF:N-(TERT-BUTOXYCARBONYL)-L-ALPHA-GLUTAMYL-N-[(1R)-1-(CARBOXYCARBONYL)-3,3-DIFLUOROPROPYL]-L-LEUCINAMIDE'>2ZF</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1bt7|1bt7]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[1bt7|1bt7]]</div></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1dxw FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1dxw OCA], [https://pdbe.org/1dxw PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1dxw RCSB], [https://www.ebi.ac.uk/pdbsum/1dxw PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1dxw ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
Revision as of 21:37, 10 March 2021
structure of hetero complex of non structural protein (NS) of hepatitis C virus (HCV) and synthetic peptidic compoundstructure of hetero complex of non structural protein (NS) of hepatitis C virus (HCV) and synthetic peptidic compound
Structural highlights
Publication Abstract from PubMedFew structures of viral serine proteases, those encoded by the Sindbis and Semliki Forest viruses, hepatitis C virus (HCV) and cytomegalovirus, have been reported. In the life cycle of HCV a crucial role is played by a chymotrypsin-like serine protease encoded at the N-terminus of the viral NS3 protein, the solution structure of which we present here complexed with a covalently bound reversible inhibitor. Unexpectedly, the residue in the P2 position of the inhibitor induces an effective stabilization of the catalytic His-Asp hydrogen bond, by shielding that region of the protease from the solvent. This interaction appears crucial in the activation of the enzyme catalytic machinery and represents an unprecedented observation for this family of enzymes. Our data suggest that natural substrates of this serine protease could contribute to the enzyme activation by a similar induced-fit mechanism. The high degree of similarity at the His-Asp catalytic site region between HCV NS3 and other viral serine proteases suggests that this behaviour could be a more general feature for this category of viral enzymes. Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain.,Barbato G, Cicero DO, Cordier F, Narjes F, Gerlach B, Sambucini S, Grzesiek S, Matassa VG, De Francesco R, Bazzo R EMBO J. 2000 Mar 15;19(6):1195-206. PMID:10716920[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||